PR Newswire·Jan 15, 2026, 8:30 AM ET

Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S.

Zydus Lifesciences Limited successfully closed its Asset Purchase Agreement, Share Purchase Agreement, and exclusive Licensing Agreement with Agenus Inc. following receipt of all regulatory approvals, including clearance from the Committee on Foreign Investment in the United States (CFIUS).
The transaction establishes Zydus' advanced manufacturing facilities in the global biologics CDMO business under a new U.S. subsidiary named Zylidac Bio LLC.
Zylidac Bio LLC will provide biologicals manufacturing sites offering CDMO services globally, prioritizing secure, domestic, & high-quality supply chains for advanced therapies in compliance with the BIOSECURE Act.
Under the exclusive manufacturing agreement, Zydus will serve as the sole provider for the production of drug substance & drug product for Agenus' Phase 3 immuno-oncology candidates, Botensilimab (BOT) & Balstilimab (BAL).
Zydus secured exclusive rights to commercialize Agenus' lead immuno-oncology assets, BOT & BAL, in India & Sri Lanka.
Zydus completed an equity investment in Agenus Inc. through its venture capital arm, Zynext Ventures.
The deal complements Zydus' strategic partnership with Formycon to commercialize the Keytruda biosimilar FYB206 in North America, ensuring a localized supply chain for its expanding portfolio.
Earlier in 2025, Zydus announced Global BioCDMO Services through the acquisition of Agenus' state-of-the-art facilities located in Emeryville & Berkeley.